S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
FuelCell Is Back To Realistic Valuation
New Mexico reaches $500M settlement with Walgreens in opioid case
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Nigeria's central bank chief arrested after being suspended by president
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
Oregon Democratic Party to send federal officials a $500,000 donation from former FTX executive
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
FuelCell Is Back To Realistic Valuation
New Mexico reaches $500M settlement with Walgreens in opioid case
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Nigeria's central bank chief arrested after being suspended by president
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
Oregon Democratic Party to send federal officials a $500,000 donation from former FTX executive
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
FuelCell Is Back To Realistic Valuation
New Mexico reaches $500M settlement with Walgreens in opioid case
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Nigeria's central bank chief arrested after being suspended by president
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
Oregon Democratic Party to send federal officials a $500,000 donation from former FTX executive
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
FuelCell Is Back To Realistic Valuation
New Mexico reaches $500M settlement with Walgreens in opioid case
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Nigeria's central bank chief arrested after being suspended by president
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
Oregon Democratic Party to send federal officials a $500,000 donation from former FTX executive
ETR:EVT

Evotec (EVT) Stock Forecast, Price & News

€22.56
-0.30 (-1.31%)
(As of 06/9/2023 ET)
Compare
Today's Range
€22.41
▼
€23.18
50-Day Range
€16.27
▼
€22.86
52-Week Range
€14.80
▼
€29.71
Volume
472,752 shs
Average Volume
1.36 million shs
Market Capitalization
$3.99 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
€31.83
ProfileAnalyst RatingsChartCompetitorsHeadlines

EVT stock logo

About Evotec (ETR:EVT) Stock

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Receive EVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter.

EVT Stock News Headlines

June 8, 2023 | markets.businessinsider.com
Citi upgrades Evotec AG (EVO) to a Buy
June 8, 2023 | msn.com
WARBURG RESEARCH GMBH Maintains Evotec SE (FWB:EVT) Buy Recommendation
June 10, 2023 | Behind the Markets (Ad)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
June 5, 2023 | finanznachrichten.de
Evotec SE: Evotec Presents Sustainability Strategy
June 5, 2023 | markets.businessinsider.com
EQS-News: Evotec presents sustainability strategy
June 2, 2023 | finanznachrichten.de
Evotec SE: Evotec Receives Grant from Open Philanthropy for Discovery of RNA-Targeting Henipavirus Therapeutics
May 9, 2023 | markets.businessinsider.com
EQS-Adhoc: Just Evotec Biologics enters strategic biosimilars partnership with Sandoz
May 9, 2023 | markets.businessinsider.com
EQS-News: Just Evotec Biologics launches tech partnership for biosimilars development and commercial manufacturing
June 10, 2023 | Altimetry (Ad)
Surprising "Twist" Hands Biden Landslide Re-election?
This could make it harder than ever to hang onto the money you make as Progressives gain power, and America slides further towards Socialism.
May 9, 2023 | finance.yahoo.com
Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial Manufacturing
April 10, 2023 | markets.businessinsider.com
EQS-News: Evotec SE provides update on cyber attack
March 31, 2023 | americanbankingnews.com
Deutsche Bank Aktiengesellschaft Reiterates €21.00 Price Target for Evotec (ETR:EVT)
March 30, 2023 | americanbankingnews.com
Royal Bank of Canada Analysts Give Evotec (ETR:EVT) a €28.00 Price Target
March 30, 2023 | americanbankingnews.com
Warburg Research Reiterates €29.00 Price Target for Evotec (ETR:EVT)
March 28, 2023 | uk.finance.yahoo.com
Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership
March 28, 2023 | finanznachrichten.de
Evotec SE: Evotec and Bristol Myers Squibb Extend and Expand Strategic Neurodegeneration Partnership
March 28, 2023 | markets.businessinsider.com
EQS-News: Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership
March 28, 2023 | finance.yahoo.com
Evotec and Bristol Myers Squibb Extend and Expand Strategic Neurodegeneration Partnership
March 28, 2023 | americanbankingnews.com
Jefferies Financial Group Analysts Give Evotec (ETR:EVT) a €34.00 Price Target
March 28, 2023 | markets.businessinsider.com
EQS-News: Evotec SE preliminary fiscal year 2022 results: 'Ahead of the curve' very strong performance in a challenging year
March 28, 2023 | finance.yahoo.com
Evotec SE Preliminary Fiscal Year 2022 Results: 'Ahead of the Curve' - Very Strong Performance in a Challenging Year
March 24, 2023 | finanznachrichten.de
Evotec SE: Evotec Receives US$ 6.6 m Grant for Drug Discovery in Tuberculosis
March 24, 2023 | markets.businessinsider.com
EQS-News: Evotec receives US$ 6.6 m grant for drug discovery in tuberculosis
March 24, 2023 | fxstreet.com
Concerns over banking sector impedes risk appetite
March 24, 2023 | finance.yahoo.com
Evotec Receives US$ 6.6 m Grant for Drug Discovery in Tuberculosis
March 16, 2023 | finanznachrichten.de
Evotec SE: Evotec Announces Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb
March 16, 2023 | finance.yahoo.com
Evotec Announces Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb
See More Headlines

EVT Price History

Industry, Sector and Symbol

Stock Exchange
ETR
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
ETR:EVT
CUSIP
N/A
CIK
N/A
Web
www.evotec.com
Phone
+49-40-560810
Fax
N/A
Employees
4,081
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
€31.83
High Stock Price Forecast
€47.00
Low Stock Price Forecast
€21.00
Forecasted Upside/Downside
+41.1%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

EPS (Most Recent Fiscal Year)
(€1.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
73.11
P/E Growth
0.98
Net Income
$-175,660,000.00
Net Margins
-23.38%
Pretax Margin
N/A
Return on Equity
-13.70%
Return on Assets
0.57%

Debt

Debt-to-Equity Ratio
42.68
Current Ratio
3.18
Quick Ratio
2.97

Sales & Book Value

Annual Sales
$751.45 million
Price / Sales
5.31
Cash Flow
€6.54 per share
Price / Cash Flow
3.45
Book Value
€6.72 per share
Price / Book
3.36

Miscellaneous

Outstanding Shares
176,950,000
Free Float
N/A
Market Cap
$3.99 billion
Optionable
Not Optionable
Beta
1.05

Key Executives

  • Dr. Werner Lanthaler M.B.A. (Age 55)
    MBA, MPA, Ph.D., Chairman of Management Board & CEO
    Comp: $1.3M
  • Mr. Enno Spillner (Age 53)
    CFO & Member of Management Board
    Comp: $604k
  • Dr. Cord Dohrmann Ph.D. (Age 59)
    Chief Scientific Officer & Member of Management Board
    Comp: $726k
  • Dr. Craig Johnstone (Age 53)
    COO & Member of Management Board
    Comp: $616k
  • Dr. Matthias Evers (Age 50)
    Chief Bus. Officer & Member of Management Board
  • Ms. Anja Bosler
    Principal Accounting Officer and Sr. VP of Group Accounting
  • Mr. Volker Braun
    Sr. VP and Global Head of Investor Relations & ESG
  • Dr. Christian Dargel
    EVP Global Head of Legal & Compliance
  • Gabriele Hansen
    Sr. VP & Head of Global Corp. Communications & Marketing
  • Ms. Monika Conradt
    Global Head of HR

Key Competitors

View All Competitors













EVT Stock - Frequently Asked Questions

What is Evotec's stock price forecast for 2023?

0 Wall Street research analysts have issued 12 month price objectives for Evotec's shares. Their EVT share price forecasts range from €21.00 to €47.00. On average, they expect the company's stock price to reach €31.83 in the next twelve months. This suggests a possible upside of 41.1% from the stock's current price.
View analysts price targets for EVT or view top-rated stocks among Wall Street analysts.

How have EVT shares performed in 2023?

Evotec's stock was trading at €15.26 at the beginning of 2023. Since then, EVT stock has increased by 47.8% and is now trading at €22.56.
View the best growth stocks for 2023 here.

What other stocks do shareholders of Evotec own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evotec investors own include Agilent Technologies (A), AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD), Anthem (ANTM), AxoGen (AXGN), Bank of America (BAC), Booz Allen Hamilton (BAH), Biohaven (BHVN), Biogen (BIIB) and Blueprint Medicines (BPMC).

What is Evotec's stock symbol?

Evotec trades on the ETR under the ticker symbol "EVT."

What is Evotec's stock price today?

One share of EVT stock can currently be purchased for approximately €22.56.

How much money does Evotec make?

Evotec (ETR:EVT) has a market capitalization of $3.99 billion and generates $751.45 million in revenue each year. The company earns $-175,660,000.00 in net income (profit) each year or (€1.01) on an earnings per share basis.

How many employees does Evotec have?

The company employs 4,081 workers across the globe.

How can I contact Evotec?

Evotec's mailing address is Essener Bogen 7, HAMBURG, 22419, Germany. The official website for the company is www.evotec.com. The company can be reached via phone at +49-40-560810.

This page (ETR:EVT) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -